Connect with us

Featured Stocks

TILT Holdings Inc (OTCMKTS: SVVTF) in the Spotlight – Upward Trajectory is the Main Focus

Published

on

Tilt Holdings

While it could be a little hard for some to wrap their heads around Tilt Holdings Inc (OTCMKTS: SVVTF), it still could pay off well for marijuana investors.

The pot company completed a four-way reverse merger as well as began trading on the Canadian Securities Exchange last year. Tilt offers distribution of products with the final mile delivery of goods to various dispensaries through its Blackbird subsidiary, and CRM Software to the retailers to help with the purchase.

Tilt Holdings Share Price Analysis

Tilt has shown an archetypal ‘pullback play’ amid a correction that saw a shift from a record high of 3 USD a share this year to a current 1.62 USD per share. Notably, the upward trend has again started to gain some pace so far.

SVVTF Daily Chart

After bottoming, Tilt Holdings is set for a run to get back to over $3 a share which is the immediate resistance. A rally and then a close; that level will undoubtedly affirm a long-term uptrend which will set the pace for stock to edge higher.

TILT Holdings Inc. Overview

Tilt Holdings Inc. is a Canada-based company that delivers products as well as services across the marijuana industry. It provides them through knowledge-based technology systems for both consumers and businesses.

The company went public in early December via a reverse merger in Canada, which allowed it to be listed after making 119 million in the capital at about $4 per share.

The company released its Q4 2018 financial as well as operational highlights whereby it raised $125 million between a strategic private placement offering and a private placement offering with Weston Capital.

During 2018 it was listed on the Canadian Securities Exchange and closed the merger of 4 complementary businesses which evidently provided a foundation for Tilt Holdings.

Also, the pot stock reported revenue of $5.1 million, which was a massive step up compared to the prior year that was nil. Besides, there was a pro forma revenue of $32.8 million. Furthermore, adjusted EBITDA was $3.3 million with that of the prior year being $4.1 million.

Tilt Holdings Acquisition Drive

For any stock to skyrocket, acquisitions have to be behind the wheel, and Tilt Holdings has done its part with a robust of acquisition drive.

Since the year started, the firm has completed a plethora of acquisitions which would prove significant in strengthening its growth. Tilt kick-started the year with the acquisition of Jupiter Research, enabling it to gain access to the leading inhalation as well as vaporization Technology firm.

Having booked over 105 million USD orders in 2018, Jupiter Research also enables Tilt to broaden its product offerings as well as bolster the company.

Furthermore, after Jupiter Research, Tilt acquired Blackbird Holdings which is all set to strengthen its logistics operations as well as software solutions in the marijuana sector. Also, it will support the company’s offering expansion to cannabis business customers and owners.

To ensure that Tilt expands its infrastructure platform and add access to its 13 million customers, it acquired Standard Farms LLC. Standard Farms will also strengthen its product lines since its products circulate in almost 95% of the Pennsylvania dispensaries.

Moreover, the company secured a $20 million credit facility that will strengthen its financial profile – that is undoubtedly a massive step to a larger raise.

What’s Up for the MJ Stock?

One thing that stands out is that Tilt Holdings is among the largest US revenue producing cannabis firms. With the latest change in Tilt’s management, whereby they have named Mark Scatterday as an interim CEO, the company’s sturdy revenue growth is set to continue this year.

Therefore, it looks an ideal play for early movers who eye an opportunity in the marijuana sector given its continuation in expanding its footprint. 

For the latest updates on SVVTF and the hottest MJ stocks, sign up below!

Disclosure: We have no position in SVVTF and have not been compensated for this article.

Image courtesy of Pexels

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Featured Stocks

Why Lexaria Bioscience Corp (OTCMKTS:LXRP) Is A Comeback Play

Published

on

Lexaria Bioscience

Lexaria Bioscience Corp (OTCMKTS:LXRP) brightest days lie ahead. The sentiments shared by Chief Executive Officer, Chris Bunka, are slowly coming to fruition, going by recent price action activity. After a steep pullback in 2019, the stock has once again started climbing higher, as investors react to milestones achieved in 2019 that affirm long-term prospects.

Lexaria Bioscience Catalysts and Price Analysis

A confirmation that the global innovator in drug delivery systems achieved almost everything it set out to accomplish in 2019 continues to strengthen market sentiments. The inking of strategic partnerships with Fortune 500 style companies is another development that the management continues to tout.

Likewise, Lexaria Bioscience succeeded in getting its DehydraTECH technology to market, consequently creating an avenue for generating long-term value. The company’s Intellectual Property strategy has also started to pay dividends, affirming what is at stake going forward. Reports that the company is already experiencing an increase in revenues is another catalyst that continues to shore the stock’s sentiments and prospects in the markets.

Lexaria Bioscience has already started bottoming out from all-time lows in what appears to be the development of a positive trend. A 10% plus rally from one-year lows continue to fuel optimism that the stock has clocked a bottom and due for a correction higher.

Standing in the way of the emerging uptrend is the $0.50 mark, which is the immediate short-term resistance level. A rally followed by a close above the…

Continue Reading

Featured Stocks

Helix TCS Stock (OTCMKTS:HLIX): A Fundamentally Attractive Investment

Published

on

Helix TCS stock

Helix TCS Stock (OTCMKTS:HLIX) is turning out to be an interesting pick after a steep pullback in 2019. The stock appears to be trading at a big discount going by the solid fundamentals that support a bounce back from current lows. If you are looking for a company seeing plenty of opportunities on the horizon then Helix TCS stock fits the bill.

Helix TCS Stock Catalysts and Price Analysis

The company is currently ranked at number 32 on the Deloitte Technology 500 fastest growing companies. The impressive rating stems from the company reporting impressive financial results depicted by an 80% increase in revenue and a 39% increase in cash flow from operations.

Likewise, the company has moved to strengthen its prospects in the hemp business by launching the nation’s first hemp tracking system. Similarly, the company has inked a strategic partnership with Alt Thirty Six for the launch of digital payments targeting thousands of dispensaries across the U.S

Reports that Helix TCS BioTrack traceability stem processed over $11 million transactions in the first week of recreational sales attest to what could turn out to be a break out year for the company and its technology.

It thus does not come as a surprise that the company’s stock has started to pick up some steam after a roller coaster 2019. A 10% plus rally since the start of the year affirms renewed investor interest in response to the wave of…

Continue Reading

Featured Stocks

Why OWC Pharmaceutical Research Corp (OTCMKTS:OWCP) Is A Promising Stock In 2020

Published

on

OWC Pharmaceutical Research

In 2020, investors are looking for cannabis stocks that can deliver excellent returns following a disappointing 2019, which saw many pot stocks crash to multiyear lows. OWC Pharmaceutical Research Corp (OTCMKTS:OWCP) stands out as a promising cannabis stock to own in 2020.

About OWC Pharmaceutical Research

The cannabis stock universe is vast, so for investors who may have just come across OWC Pharmaceutical for the first time an introduction of the company is in order.

OWC Pharmaceutical is an Israel-based cannabis research company. It is focused on research and development of cannabis-based medical products. The company’s work currently includes development of cannabis-based treatments for a variety of diseases and disorders such as multiple myeloma, psoriasis and fibromyalgia.

Moreover, OWC Pharmaceutical provides consulting services to both government and private entities in the field of medical cannabis programs.

OWC Pharmaceutical Research exited 2019 on a high note

While 2019 ended up being one of the toughest year for cannabis stocks, OWC Pharmaceutical had strong finish to the year. The stock gained 35% on December 31. Before that, the stock rose 65% on December 30. The back-to-back gains in the final days of 2019 helped OWC Pharmaceutical cut its losses for the year but also signaled improving investor sentiment on the stock heading into the new year.

OWC Pharmaceutical finished 2019 at $0.089, having pulled from a low of $0.0045 at the beginning of December.

What…

Continue Reading

MJ Stocks